Misha Blagosklonny of Oncotarget



Misha Blagosklonny of Oncotarget

Misha Blagosklonny of Oncotarget

Welcome to mishablagosklonny.com. Misha Blagosklonny is one of the Editor-in-Chiefs at Oncotarget. The Editorial board at Oncotarget includes the most prominent cancer researchers in the world. In fact, Misha Blagosklonny is proud to say that during a short history of Oncotarget many Editorial Board members have become members of the National Academy of Sciences USA, won Lasker, Nobel and other prestigious awards.

The story of Mikhail (Misha) V. Blagosklonny started when he graduated with an MD and PhD from First Pavlov State Medical University of St. Petersburg, Russia. Dr. Misha Blagosklonny of Oncotarget then moved to the United States where he became famous for contributions to  the research of cancer and aging.

Everything Dr. Misha Blagosklonny of Oncotarget contributes to is to further understand the cause of cancer and find an efficient treatment. Soon,  Misha Blagosklonny and  Oncotarget will once again be a major part of the Ride for Roswell. The Ride for Roswell is a community event in Buffalo, New York where funds are raised for the Roswell Park Cancer Center, the biggest cancer center in Upstate New York.  Mikhail Blagosklonny is proud to say that Oncotarget has been sponsoring the event for the past two years.

This website will serve as a place for Mikhail  Blagosklonny of Oncotarget to inform the public on the latest news and information in cancer research.

http://www.mishablagosklonny.com/


When general population discuss contemporary medicine, accuracy plays one of the most crucial roles and human lives are directly dependent on it. Likewise, any researches pertaining to medicine are necessary to comply with the top standards. The challenge nowadays is that any recommendations of researches can be published online and used as a reference without being thoroughly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and tried to create an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That assists both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website provides a full publications list with respective scores higher than 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the required help to anybody, who has interest in oncology.
Zoya Demidenko
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and written by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Likewise, the article about melanoma, was utilized for citations in different news articles 69 times. Moreover, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get helpful scientific facts. Oncotarget is glad to have the chance to share with online viewers this highly appreciated and top-quality information, that is trustworthy and reliable.
https://peterattiamd.com/targeting-aging/

Comments

Post a Comment

Popular posts from this blog

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma ABSTRACT Although new analogues of immunomodulatory drugs (IMiDs) are being developed for MM, the molecular mechanism of these drugs remains unclear. In the current study, we used MM cell lines as a model to investigate the molecular mechanism of thalidomide and to compare its potency with IMiDs such as pomalidomide. We determined that thalidomide did not inhibit cell proliferation of RPMI8226 and U266 MM cells, whereas pomalidomide showed a significant inhibitory effect on these two MM cell lines. Interestingly, we further demonstrated that although thalidomide down-regulated bFGF translation through the inhibition of IRES even at 0.1 µg/ml, pomalidomide did not have a similar affect bFGF levels. A colony formation assay demonstrated that thalidomide and the bFGF knock-down clones caused a significant reduction in the clonogenic ability of MM cells, and treatment with exogenous ...
Read more

Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells

Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells ABSTRACT Neuroblastoma is the most common extracranial tumor in childhood. Outcome of stage 4 disease remains poor and the development of novel therapeutic approaches is thus urgently needed. Taurolidine (TRD), originally invented to avoid catheter infections, has shown to exhibit antineoplastic activity in various cancers. The growth of neuroblastoma cell lines is inhibited by TRD as recently demonstrated. Further analysis disclosed a significant negative growth effect of TRD on the four neuroblastoma cell lines SH-EP TET21N, SK-N-AS, SK-N-BE(2)-M17 and SK-N-SH. Detected IC 50  (51-274 µM; 48 h) are promising and correspond to clinically- achievable plasma levels. Apoptosis was induced (76-86%; 48 h) in a time- dependent manner mediated by a simultaneous activation of the intrinsic and extrinsic pathways. This was confirmed by cleavage of caspases -3, -8 and -9 and abrogation of apoptosis by pan-caspase inhibi...
Read more